US pharmaceutical company MannKind Corporation will share findings from their pioneering research project INHALE-3 later this month at the American Diabetes Association’s Scientific Sessions in Orlando.
INHALE-3 is a study of 141 participants over 18 years of age with T1D who are using an automated insulin delivery system or a pump without automation. Participants either continued with their standard of care or initiated an insulin regimen of a daily basal injection plus Afrezza (powdered insulin through inhalation) for boluses at meals.
Focusing on improving mealtime control, initial findings from the clinical trial suggest that inhaled insulin can better meet the need for greater control and flexibility. This is definitely one to keep a closer eye on if it helps to improve mealtime management for type 1 diabetics.
Crumbling Pavlova 
Leave a comment